This narrative review examines the role of X chromosome inactivation escape and XCI skewing in female cells. The authors discuss how these genetic mechanisms might connect to autoimmune disorders, neurodevelopmental disorders, cardiovascular diseases, and cancer. The study does not report a specific sample size or clinical trial data. No safety concerns or adverse events were reported because this is a review of existing literature rather than a new experiment. Readers should understand that this work summarizes known associations and does not prove that these genetic patterns cause disease. The main reason to be careful is that the evidence comes from a narrative review, which means it synthesizes past findings without new data collection. Readers should take from this that X chromosome inactivation escape is a biological process worth studying in the context of female health. More research is needed to confirm if these patterns directly drive disease risk or if they are simply markers of underlying biology.
X chromosome inactivation escape patterns in female cells
Photo by New Material / Unsplash
What this means for you:
This narrative review links X chromosome inactivation escape to several diseases in female cells. More on Cancer
Narrative review discusses SECTM1 for cancer, cardiovascular disorders, and neurodegenerative diseases without reported outcomes or safety data A narrative review looks at SECTM1 for cancer and other serious conditions
Frontiers · May 23, 2026
Narrative review explores bromelain's potential across multiple chronic diseases Bromelain shows promise for several diseases but needs more human testing
Frontiers · May 21, 2026
Narrative review discusses extracellular vesicles as biomarkers for cancer, neurological disorders, and cardiovascular diseases Extracellular vesicles show promise as biomarkers for multiple diseases
Frontiers · May 19, 2026
Narrative review of risk perception tools for chronic disease patients Your Health Worries Could Predict Your Future Disease Risk
Frontiers · May 8, 2026